Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.51 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23639222 | 0.76 | SMARCA2 (0.51) | SMARCA2SMARCA4LOXL2LOXHDAC4 | |
| SCHEMBL30505955 | 0.76 | LOXL2 (0.52) | SMARCA2SMARCA4LOXL2LOXHDAC4 | |
| SCHEMBL9234478 | 0.76 | SMARCA2 (0.51) | SMARCA2SMARCA4LOXL2LOXHDAC4 | |
| SCHEMBL30016319 | 0.76 | SMARCA2 (0.51) | SMARCA2SMARCA4LOXL2LOXHDAC4 | |
| SCHEMBL2479367 | 0.76 | LOXL2 (0.52) | SMARCA2SMARCA4LOXL2LOXHDAC4 | |
| SCHEMBL2443379 | 0.75 | SMARCA2 (0.51) | SMARCA2SMARCA4LOXL2LOXHDAC4 | |
| SCHEMBL19392146 | 0.74 | SMARCA2 (0.45) | SMARCA2SMARCA4LOXL2TAS2R14MGLL | |
| SCHEMBL23176327 | 0.74 | SMARCA2 (0.45) | SMARCA2SMARCA4LOXL2LOXHDAC4 | |
| SCHEMBL28200272 | 0.74 | HDAC1 (0.50) | — | |
| Hydrochloric Acid SCHEMBL31696645 | 0.74 | LOXL2 (0.53) | SMARCA2SMARCA4LOXL2LOXHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-8017612-B2 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2011-09-13 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | SMARCA2 4188/4885SMARCA4 4332/4885LOXL2 4056/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | SMARCA2 3822/4885SMARCA4 3502/4885LOXL2 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.